BTRC and neoplasm: In contrast, BT474-derived tumor size was reduced following trastuzumab administration (Fig. 2Q–U), while overexpression of circ-β-TrCP significantly attenuated the therapeutic effect of trastuzumab (Fig. 2Q–U).